Intel stock spikes after report of possible US government stake
Dier Mardi, the Senior Vice President and Chief Financial Officer of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), recently sold a portion of her holdings in the company. The biotech firm, currently valued at $7.2 billion, has seen its stock surge over 42% in the past six months, according to InvestingPro data. According to a regulatory filing, Mardi disposed of 258 shares of common stock on March 10, 2025, at a price of $323.04 per share. The transaction amounted to a total value of $83,344. Following this sale, Mardi retains ownership of 10,440 shares in the company. The sale was executed under a pre-established Rule 10b5-1 trading plan, which Mardi adopted on November 13, 2024. InvestingPro analysis shows the company maintains strong financial health with a current ratio of 6.1, while analysts have set price targets ranging from $236 to $539. Get access to 12 additional ProTips and comprehensive financial analysis with an InvestingPro subscription.
In other recent news, Madrigal Pharmaceuticals reported its fourth-quarter and full-year 2024 earnings, with revenues reaching $103 million and $180 million, respectively, hitting the upper end of their preannounced range. This financial performance aligns with optimistic projections from analysts, including UBS, which reaffirmed a Buy rating and a $441 price target, citing the company’s promising commercial trajectory. Additionally, JMP Securities raised its price target for Madrigal to $443, following new data showing significant improvements in liver stiffness among patients treated with Rezdiffra. H.C. Wainwright also adjusted its price target to $405, maintaining a Buy rating based on positive growth prospects.
Madrigal Pharmaceuticals announced the appointment of Jacqualyn Fouse, Ph.D., to its Board of Directors, succeeding Fred Craves, Ph.D., who will retire in July 2025. The company is also anticipating a regulatory decision from the European Medicines Agency regarding Rezdiffra by mid-2025, with plans for a product launch in Germany later that year. These developments come as the company continues to advance its clinical program, with the Phase 3 MAESTRO-NASH Outcomes trial expected to yield results in 2027. The ongoing trials and strategic leadership changes reflect Madrigal’s commitment to addressing the unmet needs in the treatment of NASH.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.